Filling the need for trusted information on national health issues…

Trending on kff Open Enrollment Medicare Part D Medicaid Expansion

Kaiser Daily Global Health Policy ReportVaccines Search Results « » The Henry J. Kaiser Family Foundation


  • your selections
Clear Search

Filter Results



  • results
CDC, Surgeon General Report On Increased Number Of H1N1 Cases In Southeast U.S.

Although H1N1 (swine flu) “has waned across much of the United States, the southeast is reporting an increase in cases of the H1N1 virus, U.S. health officials said on Monday,” Reuters reports. During a conference call with reporters, Anne Schuchat of the CDC reported an uptick in the number of H1N1 cases reported in Alabama, South Carolina and Georgia (Allen, 3/29).

GlaxoSmithKline, Pfizer Will Supply 600M Doses Of Reduced-Price Pneumococcal Vaccines To Developing Countries Over 10 Years, GAVI Says

The GAVI Alliance on Tuesday formally announced that drugmakers GlaxoSmithKline and Pfizer had signed off on a “10-year deal … to supply 60 million doses a year of cut-price pneumococcal vaccines to developing nations,” Reuters reports. The agreement is under what’s “called an Advance Market Commitment (AMC) which guarantees a market for vaccines supplied to poor nations but sets a maximum price drugmakers can expect to receive,” the news service writes (Kelland, 3/23).

Also In Global Health News: Bird Flu In Hong Kong; Counterfeit Drugs In Africa; Dep. Sec. Of State For Management, Resources; HIV/AIDS In S. Africa; World Toilet Day

Bird Flu Case In Hong Kong Isolated Health officials in Hong Kong confirmed on Monday that the woman diagnosed with H5N1 (bird) flu after a trip to China this month is now in stable condition and did not contract a new strain of the virus, SAPA/DPA/Mail & Guardian report. Additionally, her case appears…

Report Documents Increase In R&D Projects On Developing World Diseases

“Drugmakers are now working on over 100 R&D projects designed to tackle diseases of the developing world and almost 80% of them are being carried out with non-industry partners,” according to a report (.pdf) released on Wednesday by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), Pharma Times reports.

U.N. Agencies, Rotary International Launch Mass Polio Immunization Campaign In Central Africa

The WHO, UNICEF and Rotary International on Thursday announced they will kick off a “mass polio immunization campaign in three Central African nations” on Friday “in response to a polio outbreak suspected in more than 100 deaths and deemed ‘unusual’ because it targets adults more than children,” that was first confirmed in the Republic of Congo on Nov. 4, the Associated Press reports.

Also In Global Health News: TB In Papua New Guinea; Plasmodium Vivax Malaria Vaccine; Drugs For Chagas, Leishmaniasis; Pakistan Aid Concerns; HIV Among Pregnant Women In SA

Officials Highlight TB Control Concerns In Papua New Guinea Three years into Papua New Guinea’s (PNG) five-year $19 million tuberculosis control plan, program funders and local health authorities are expressing concerns about its progress, IRIN reports. “In comparison with other countries … coverage of treatment in PNG is lagging behind,” said Marcela Rojo,…

Scientists Identify Genes That Enable Some Immune Systems To Halt HIV; Finding Could Spur Drug, Vaccine Development

“Tiny variants in a protein that alerts the body to infection could explain how one in 300 HIV-infected people are able to resist the onset of AIDS for years without needing any treatment, researchers said Thursday” in a study published online in the journal Science, Agence France-Presse reports (11/4). “The findings are encouraging for the development of vaccines because they tell scientists how the immune system might be manipulated to fend off HIV,” the Independent writes (Connor, 11/5).

Sanofi Pasteur’s Dengue Vaccine Enters Phase III Trial In Australia

Sanofi Pasteur, the vaccines division of the pharmaceutical group Sanofi-Aventis, on Thursday announced the company had begun testing its dengue fever vaccine in a Phase III clinical trial in Australia, Dow Jones/Wall Street Journal reports. “Sanofi-Aventis already performed earlier clinical tests on children and adults with the vaccine in the U.S., Asia and Latin America,” Dow Jones/Wall Street Journal adds (Landauro, 11/4).